B. Riley Upgrades Eton Pharmaceuticals (NASDAQ:ETON) to Strong-Buy

Eton Pharmaceuticals (NASDAQ:ETON) was upgraded by equities researchers at B. Riley to a “strong-buy” rating in a research note issued on Thursday,Zacks.com reports.

Several other analysts have also weighed in on ETON. HC Wainwright increased their price target on Eton Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a report on Monday, January 6th. Craig Hallum raised their price objective on Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday.

Eton Pharmaceuticals Stock Performance

ETON stock opened at $13.44 on Thursday. The business’s 50-day moving average is $11.64 and its two-hundred day moving average is $7.35. Eton Pharmaceuticals has a fifty-two week low of $3.03 and a fifty-two week high of $15.00. The company has a market cap of $350.13 million, a price-to-earnings ratio of -61.09 and a beta of 1.38.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ETON. Nantahala Capital Management LLC purchased a new position in shares of Eton Pharmaceuticals in the 2nd quarter valued at $3,095,000. Westside Investment Management Inc. raised its stake in shares of Eton Pharmaceuticals by 5.7% in the 3rd quarter. Westside Investment Management Inc. now owns 618,675 shares of the company’s stock valued at $3,711,000 after purchasing an additional 33,275 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Eton Pharmaceuticals by 13.5% during the 3rd quarter. Geode Capital Management LLC now owns 272,696 shares of the company’s stock worth $1,637,000 after buying an additional 32,365 shares during the last quarter. Parkman Healthcare Partners LLC boosted its holdings in Eton Pharmaceuticals by 2.8% in the third quarter. Parkman Healthcare Partners LLC now owns 260,226 shares of the company’s stock worth $1,561,000 after purchasing an additional 7,029 shares during the period. Finally, Wasatch Advisors LP acquired a new stake in Eton Pharmaceuticals during the third quarter worth about $1,431,000. Hedge funds and other institutional investors own 27.86% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.